Search

Effective treatment of aging patients with hematological diseases discussed during SWG Aging meeting in Poland

The progress in the field of aging and the optimal and rational approaches of "fit" and "unfit" older patients with malignant hemopathies was the focus of the three-day EHA-SWG Scientific Meeting on Aging and Hematology held on October 12-14, 2018 in…

Read more

Publication of EHA Annual General Meeting 2024 minutes

The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024. Scheduled on Friday during the EHA Annual Congress, the meeting was once more in a hybrid format.

Read more

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

With the Scientific Working Group for Stem Cells, the 18th Congress of EHA took the opportunity to acknowledge the work of the 2013 winner of the Nobel Prize for Medicine or Physiology, Drs John B.

Read more

Rebuilding the future for hematology in Ukraine today

The Hague (Netherlands), December 5, 2022 - Nearly 8 million Ukrainians have fled their country since February 24 according to the UN Refugee Agency, while about 5 million people have moved back.

Read more

EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies

In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)

Online registration is closed.

Read more

European Hematology Association publishes new journal with Wolters Kluwer

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more